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Abstract
The inhibition of thrombin is one of the important treatments of pathological blood clot formation. Variegin, isolated from
the tropical bont tick, is a novel molecule exhibiting a unique ‘two-modes’ inhibitory property on thrombin active site
(competitive before cleavage, noncompetitive after cleavage). For the better understanding of its function, we have
determined the crystal structure of the human a-thrombin:synthetic-variegin complex at 2.4 A ˚ resolution. The structure
reveals a new mechanism of thrombin inhibition by disrupting the charge relay system. Based on the structure, we have
designed 17 variegin variants, differing in potency, kinetics and mechanism of inhibition. The most active variant is about 70
times more potent than the FDA-approved peptidic thrombin inhibitor, hirulog-1/bivalirudin. In vivo antithrombotic effects
of the variegin variants correlate well with their in vitro affinities for thrombin. Our results encourage that variegin and the
variants show strong potential for the development of tunable anticoagulants.
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Introduction
Serine proteinases in the blood coagulation cascade are
important molecules in maintaining the integrity of hemostasis.
Among them, thrombin (factor IIa) plays significant pro- and anti-
coagulation roles. The active site contains the classical catalytic
triad – His57, Asp102 and Ser195 (Figure 1A). Compared to other
blood coagulation serine proteinases, thrombin has a prominent
active site cleft, which is deep and narrow. Two insertion loops
(called the 60-loop with residues Leu59-Asn62 and the autolysis-
loop, residues Leu144-Gly150) form the wall of the cleft
(Figure 1A–B) [1,2]. The thrombin active site surfaces that
interact with substrate residues, at N-terminal to the scissile bond,
are described as ‘non-prime subsites’ (S subsites). Similarly, the
surfaces of the active site which are in contact with substrate
residues, at C-terminal to the scissile bond, are described as ‘prime
subsites’ (S9 subsites) (Figure 1B).
In addition, exosite-I is the surface near the prime subsites. The
bottom of exosite-I is a deep, canyon-like cleft that extends from
the prime subsites. The walls of the cleft are formed by two surface
loops, Phe34-Leu39 (described as the 34-loop) and Lys70-Glu80
(the 70-loop) [2,3]. In contrast to the apolar nature of the canyon-
like cleft, the surface of exosite-I is dominated by several positively-
charged residues [4]. Exosite-II, another surface near the ‘non-
prime subsites’, is even more basic (Figure 1B). The occupancy of
either exosites can induce allosteric changes to the active site to
enhance catalysis. The binding of Na
+ to the Na
+ binding loop
(Cys220-Trp225) (Figure 1A) favors procoagulant functions of
thrombin whereas Na
+-free thrombin favors anticoagulant func-
tions such as increased protein C activation [5]. The activity and
fate of thrombin is directed by competition for its exosites and
differences in distribution of its substrates and cofactors [6].
Imbalances in blood coagulation may give rise to either loss of
clotting activity, leading to hemorrhagic disorders, or unwanted
clot formation, resulting in thrombosis. In particular, thrombosis
causes high morbidity and mortality due to vascular occlusion and
consequent myocardial infarction, stroke, pulmonary embolism, or
deep-vein thrombosis. Increased atherosclerosis and thromboem-
bolic disorders, associated with changing food habits and lifestyles,
are increasing the demand for anticoagulant agents [7,8]. Heparin
and warfarin are the cornerstones of anticoagulation therapy.
Unfortunately, both classes of drug have well-documented
limitations such as a narrow therapeutic window and highly
variable dose-response [9]. These limitations drive continual and
intense efforts to develop new, efficacious and safe anticoagulants,
especially for targeting specific coagulation factors [9]. Thrombin
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26367is one of the main targets for inhibition, owing to its pivotal role in
coagulation. Several direct thrombin inhibitors, such as hirudin
[10], hirulog-1/bivalirudin [11], argatroban [12] and dabigatran
[13], are currently available in the market. Among them, hirudin
and hirulog-1/bivalirudin are both developed from hematopha-
gous parasites and their success continues to inspire the search for
more novel anticoagulants from these sources [14,15].
Recently, we described variegin, a novel, fast and tight-binding
competitive inhibitor of thrombin (refers to the a form of thrombin
unless otherwise stated) isolated from the tropical bont tick,
Amblyomma variegatum [16]. Like hirudin/hirulog, variegin targets
the thrombin catalytic site and exosite-I. However, unlike other
naturally occurring thrombin inhibitors, variegin interacts with the
thrombin prime subsites in addition to exosite-I [17]. Variegin has
Figure 1. Structure of thrombin:s-variegin complex. (A) Thrombin (yellow) shown in the classical orientation in ribbon (without s-variegin).
Side chains of catalytic triad,
TAsp102,
THis57 and
TSer195 are shown in sticks (green). The 60-loop, autolysis loop and Na
+-binding loop are circled in
brown, cyan and green, respectively. Parts of thrombin forming the anion-binding exosite-I and exosite-II are circled in blue and purple, respectively.
(B) Surface representation of thrombin (yellow) in the same orientation as (a). Locations of active site specificity pocket, non-prime and prime subsites
are indicated by arrows. (C) The structure of thrombin (yellow) in the same orientation as above shown in complex with s-variegin (pink) together
with its electron density map (2Fo-Fc) shown contoured at 0.9s.( D) Surface representation of thrombin in complex with s-variegin (pink).
doi:10.1371/journal.pone.0026367.g001
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thetic variegin (s-variegin) contains only L-amino acids, while
hirulog-1/bivalirudin has a D-Phe [16]; (ii) inhibition by variegin is
about 9 times greater than hirulog-1/bivalirudin; (iii) the cleavage
product of variegin (MH22) remains tightly bound to thrombin
(about 400 fold stronger than cleaved hirulog-1/bivalirudin). Most
importantly, MH22 potently and noncompetitively inhibits
thrombin whereas cleaved hirulog-1/bivalirudin, paradoxically,
activates the function of the thrombin active site [17].
We solved the crystal structure of the thrombin:s-variegin
complex at 2.4 A ˚ resolution in order to understand the molecular
interactions between thrombin and variegin. Based on the
structure and data on thrombin inhibitors, a series of peptides
was designed to analyse the structure-function relationships. These
peptides cover a diverse spectrum of properties: potency, kinetics,
mechanism of inhibition, affinities (ranging from nanomolar to
picomolar values) with fast, slow, tight-binding and competitive
and noncompetitive inhibition. Finally, in vivo activities of selected
peptides were examined using a venous thrombosis model
involving zebrafish larvae.
Methods
Synthesis, purification and mass spectrometry of
peptides
Synthesis, purification and mass spectrometry analysis of all
peptides were performed as described elsewhere [16]. Peptides were
named withtwoalphabetsrepresentingthe firsttwo residuesin their
sequence, followed by a number representing their respective
length. Position of point mutants are added after the number and
italicized. Modifications to amino acids are indicated by superscript.
As sulfate groups are acid labile, the peptides containing
sulfotyrosine (DV24Y
sulf, DV24K10RY
sulf and MH18Y
sulf) were
cleaved from resins with 90% aqueous trifluoroacetic acid on ice
for 5 h.
X-ray crystallography
Lyophilized recombinant human thrombin [18,19] and s-
variegin were dissolved and mixed in buffer containing 50 mM
HEPES (pH 7.4) and 375 mM NaCl to final concentrations of
20 mg/ml and 3 mg/ml (1:1.5 molar ratio), respectively. Crystal-
lization was achieved using the hanging drop vapor diffusion
method. Typically, 1 ml of protein solution was mixed with 1 mlo f
precipitant buffer (100 mM HEPES buffer pH 7.4, containing 20
to 25% PEG 8000) and equilibrated against 1 ml of the precipitant
buffer at 4uC. X-ray diffraction data were collected at Beamline
X29 (National Synchrotron Light Source, NY, USA). Prior to data
collection, crystals were briefly soaked in a cryoprotectant solution
containing the mother liquor, supplemented with 25% (v/v)
glycerol. Data sets were collected using the Quantum 4 CCD
detector and were processed using HKL2000 [20]. As the x
2
values for the P1 unit-cell were better than those for the C2 unit-
cell during data integration (around 1.0 against 3.5 and above),
data were first processed under the P1 unit-cell orientation and
then transformed to the C2 orientation using the transformation
A=2c+a, B=a and C=b, where a,b,c and A,B,C are the P1 and
C2 unit-cell vectors, respectively.
The structure of thrombin:s-variegin complex was solved by the
molecular replacement method using PHASER [21] at 2.4 A ˚
resolution. The coordinates of the thrombin-hirulog-3 structure
(PDB code: 1ABI) [22] were used as a search model. Several cycles
of map fitting using program COOT [23] and refinement using
program REFMAC5 [24] with one TLS [25] group per chain of
thrombin led to convergence of R-values. The crystallographic
and refinement statistics are listed in Table 1. The correctness of
stereochemistry of the model was verified using PROCHECK
[26] and MolProbity [27]. The geometry of the thrombin
molecule is comparable to that of other structures at this
resolution. The peptide is relatively more flexible. The coordinates
of the structure were deposited with the RCSB Protein Data Bank
under the entry code 3B23. Online server PISA [28] was used to
analyze the protein-peptide interface. Throughout the manuscript,
the residues of thrombin and s-variegin are marked with
superscripted prefixes ‘T’ and ‘V’, respectively. The chymotryp-
sinogen numbering system is used for numbering the thrombin
residues, as first described here [29].
Thrombin inhibition
All peptides were assayed for their abilities to inhibit thrombin
amidolytic activity on chromogenic substrate S2238 (Chromo-
Table 1. Crystallographic data and refinement statistics.
Data set Thrombin:s-variegin complex
Crystal
Space Group P1 C2
Unit Cell Parameters (A ˚, u) a=50.8 A=124.7
b=61.58 B=50.8
c=67.3 A ˚ C=61.5 A ˚
a=98.1 AL=90
b=112.2 BE=98.7
c=89.9u GA=90u
Data collection
Resolution range (A ˚)5 0 22.4
Wavelength (A ˚) 0.9795
Total number of reflections 52,825
Unique reflections 29,154 15,137
Completeness (%) 88.1 (56.8) 98.1 (97.0)
I/sI 25.1 (7.0) 20.0 (5.4)
Redundancy 1.9 (1.7) 3.6 (3.1)
Rmerge (%) 2.4 (8.5) 5.3 (15.4)
Refinement and quality
Resolution range (A ˚)I .s(I) 822.4
Rwork 0.208
Rfree 0.259
RMSD bond lengths (A ˚) 0.01
RMSD bond angles(u) 1.22
Average B-factors (A ˚2)
Protein atoms (2450 atoms) 67.4
Water molecules (51 atoms) 66.2
Ramachandran plot
Most favored regions (%) 86.1
Additional allowed regions (%) 13.9
Generously allowed regions (%) 0
Disallowed regions (%) 0
Values in parentheses are for the last resolution shell (2.4622.40 A ˚). The
diffraction data were processed under the space group P1 and transformed to
the space group C2 using the transformation A=2c+a, B=a and C=b, where
a,b,c and A,B,C are the P1 and C2 unit-cell vectors, respectively.
doi:10.1371/journal.pone.0026367.t001
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concentration of peptide needed for 50% inhibition (IC50) and
inhibition constant (Ki) were calculated from data obtained were
fitted using Origin software (MicroCal, Northampton, MA, USA).
A detailed account for the selection and use of equations to fit the
data is available in Materials and Methods S1.
Zebrafish larvae venous thrombosis model
Zebrafish and the larvae were maintained as previously described
[30]. Intravenous microinjections of peptides were performed using
Nanoject II (Drummond, Broomall, PA, USA) with glass injection
needles. Ten nanolitres of peptides or phosphate buffered saline
(PBS) were injected into 4 days post-fertilization larvae through the
posterior cardinal vein. Laser ablation of larval veins were
performed with a pulsed nitrogen laser light pumped through
coumarin 440 dye (445 nm) (MicroPoint Laser system, Photonic
Instrument, St Charles, IL, USA) at 10 pulses/s with laser intensity
setting at 10. Laser ablation of each larvae was carried out 20 min
after microinjection of the peptide or PBS. The laser beam was
aimed at thecaudalvein around five somitestowards thecaudalend
from the anal pore and triggered for 3 s. Thrombus formation
following vein injury, due to laser ablation, was monitored and the
time taken for complete occlusion of the injured vein was recorded.
Results
Thrombin:s-variegin structure
The crystal structure of the thrombin:s-variegin complex was
determined at 2.4 A ˚ resolution (Table 1 and Figure 1C–D). The
electron density of the complex structure is well defined except for
termini residues of chain A [
T(
1HTFGSGE
1C) and
TArg15]. The
structure of thrombin in the complex superimposes well with other
thrombin structures.
Only 17 out of the 32 residues (
VHis12 to
VLeu28) of s-variegin
have well-defined density (Figure 1C). The first seven N-terminal
residues do not make direct contact with thrombin [16] and s-
variegin is cleaved by thrombin between
VLys10 and
VMet11 [16].
It is likely that the N-terminal fragment
V(
1SDQGDVAEPK
10) has
dissociated from thrombin after cleavage before crystallization. In
contrast, the C-terminal fragment MH22
V(
11MHKTAPPFD-
FEAIPEEYLDDES
32) remains bound to thrombin after cleavage
[17]. The N-terminal
VMet11 and the last five residues
V(
28LDDES
32) of the fragment are not observed, reflecting
disorder in the termini.
The C-termini of hirulog-1/-3, hirugen and hirudin have the
following sequence DFEEIPEEYL(Q), with the Gln only present
in hirudin. s-Variegin has an almost identical sequence
V(
19DFEAIPEEYLDDES
32), with four extra residues in the C-
terminus. Despite the identity, there are large differences between
their conformations. The C-terminus is disordered in the hirulog-
1/bivalirudin structure (PDB code: 2HGT) [4], forming a 310 helix
in hirulog-3 (PDB code: 1ABI) [22] and hirugen (PDB code:
1HGT [4]) and forming a full a-helical turn in sulfo-hirudin (PDB
code: 2PW8) [31]. In s-variegin, these residues remain in an
extended conformation until the last observed residues (
VLeu28).
The extra residues in C-terminus, although not observed in the
present structure may cause the peptide to adopt the fully
extended conformation (Figure S1).
Interactions with thrombin catalytic residues
The active site of thrombin in the crystal structure was
compared to the published data for the thrombin:hirugen
structure (unoccupied active site) (Figure 2). Of the three catalytic
residues, the most striking differences are with the Oc atom of
TSer195 and the orientation of the imidazole ring of
THis57. In
the thrombin:s-variegin structure,
TSer195 Oc is displaced by
1.19 A ˚, pointing towards s-variegin. Distance between
TSer195
Oc and the side chain Ne of
VHis12 is 3.35 A ˚, possibly forming
hydrogen bond (Table S1). At the same time, the distance between
Ne of
THis57 and Oc of
TSer195 increases to 3.60 A ˚ from 2.79 A ˚,
breaking the crucial strong hydrogen bond needed to form the
catalytic charge relay system. Without stabilization by the strong
hydrogen bond between
THis57 and
TSer195, the imidazole ring
of
THis57 is now rotated slightly and leads to a displacement of its
Ne by 0.56 A ˚ (Figure 2A). The newly formed hydrogen bond
between
TSer195 and
VHis12 delocalize the electrons of
TSer195
Oc, making
TSer195 a weak nucleophile and incapable of
efficiently attacking the backbone C of the substrate. This explains
the observed classical non-competitive inhibition for MH22 [17].
Interactions with prime subsites
In addition to the new hydrogen bond, the following
interactions anchor s-variegin P29 to P59 residues
V(
12HKTA
15)
to the thrombin prime subsites (Figure 3A). Besides the catalytic
residues,
TLeu41,
TCys42,
TCys58,
TTrp60D,
TLys60F and
TGlu192 are also in contact with
VHis12. Two hydrogen bonds
can be formed between
VHis12 with
TGlu39 and
TGlu192 (Table
S1). The P39 (
VLys13) interacts with
TArg35,
TGlu39,
TTrp60D,
TLys60F,
TAsn143,
TThr147, and
TGlu192. The P49 (
VThr14)
side chain is directed towards the base of the highly flexible
autolysis-loop. The side chain occupies a surface lined by
TLeu40,
TTrp141,
TGly142,
TAsn143,
TGln151 and
TGly193. Interactions
within this P39 subsite are strengthened by two hydrogen bonds
between
VThr14 with
TAsn143 and
TGln151 (Table S1). The P59
VAla is surrounded by
TGln38,
TGlu39,
TArg73 and
TGln151.
Thus there are extensive interactions between the variegin peptide
and thrombin prime subsites.
Interactions with exosite-I
s-Variegin fits firmly into the canyon-like cleft extending from
the thrombin active site to exosite-I. The walls of this hydrophobic
cleft are formed by the 60- and autolysis- loops near the active site,
and 34- and 70- loops at exosite-I, while many apolar residues in
these loops line the bottom [2,3]. s-Variegin is in close contact with
multiple residues in exosite-I as depicted in Figure 3B. All but four
residues of s-variegin (
VPhe18,
VAsp19,
VAla22 and
VGlu26) have
their side chains buried in the interfaces with thrombin (Figure 3A).
Interestingly, the high identity between C-terminus of s-
variegin, hirulog-1/-3, hirugen and hirudin are not reflected in
their respective salt bridges formation with exosite-I of thrombin.
Despite the presence of multiple anionic residues in the s-variegin
C-terminus and highly cationic exosite-I, only one strong salt
bridge is formed (
VGlu26:
TArg77A). This salt bridge (3.84 A ˚)i s
not observed in hirulog-1/-3, hirugen and hirudin structures as
TArg77A adopts a different rotamer that points away from the
inhibitor (Figure 4A and S2A). In addition, a weak salt bridge is
also likely between
VGlu21 and
TArg75 (4.64 A ˚). In hirulog-1/-3,
hirugen and hirudin structures the analogous Glu makes an ion
pair with
TArg75 of a 2 fold symmetry-related thrombin, although
this interaction is suggested to occur within the same thrombi-
n:inhibitor pair in solution [4,22,32]. In our structure, the
TArg75
side chain is rotated by 80.5u about Cb, compared to the
thrombin:hirulog-3 complex (Figure 4A and S2A) facilitating this
interation. In hirulog-1/-3 and hirugen structures, an ion pair
between
TArg73 and the Asp, analogous to
VAsp19, can be
observed. However, formation of this ion pair in the thrombin:s-
variegin complex is not possible as the
VAsp19 side chain points in
an opposite direction into solvent. This difference is most likely
A Novel Mechanism of Thrombin Inhibition
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VPro16-
VPro17 (see below) (Figure 4B–C and S2B).
The end of the canyon-like cleft is a relatively flatter surface and
formed by
TAsp63 to
TIle68 and
TLys81 to
TLeu85. The residues
VPro24 to
VTyr27 are stacked loosely on top of this surface with one
o ft h es i d ec h a i n s(
VGlu25) pointing towards solvent (Figure 3C). This
s-variegin segment is in a different conformation when compared to
hirulog-3/hirugen despite sequence similarity (Figure S1).
Design and characterization of variegin variants
Several new variegin variants were designed based on the
thrombin:s-variegin structure, as well as background information
available on thrombin:inhibitor interactions.
(a) Optimization of the length of variegin. The lack of
electron density for the last four C-terminal residues
[
V(
29DDES
32)] of s-variegin in the complex structure
Figure 2. Thrombin catalytic triads in s-variegin-bound and hirugen-bound structures. (A) Thrombin catalytic triad
THis57,
TAsp102 and
TSer195 in thrombin:hirugen structure (green) and in thrombin:s-variegin structure (pink) are superimposed. The
TSer195 Oc in thrombin:s-variegin
structure is displaced by 1.19 A ˚ compared to thrombin:hirugen structure. The displacement of
TSer195 Oc in thrombin:s-variegin structure (pink) is
due to interactions with
VHis12 of s-variegin through hydrogen bond (dotted arrow), rendering
TSer195 a weak nucleophile that is incapable of
catalysis. The imidazole ring of
THis57 also rotated, resulted in a displacement of its Ne by 0.56 A ˚. Overall, the distance between Ne of
THis57 and Oc
of
TSer195 increases to 3.60 A ˚ (black arrow) from 2.79 A ˚ (green arrow), disrupts the catalytic charge relay system. (B) The 2Fo-Fc electron density map
of thrombin catalytic triad and
VHis12 contoured at 1.0s.
doi:10.1371/journal.pone.0026367.g002
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thrombin. As these residues are also not present in hirulogs
or hirugen, two variants (EP21 and MH18) lacking the last
four C-terminal residues were synthesized and characterized.
IC50 and Ki values of EP21 and MH18 are essentially
identical with their templates (EP25 and MH22, respectively)
and indicate that the truncation of the four C-terminal
residues does not alter the inhibitory activity (Table 2).
Previously, we have shown that the first seven N-terminal
residues of variegin [
V(
1SDQGDVA
7)] are responsible for its fast-
binding kinetics, due to a possible steering effect towards the highly
basic thrombin exosite-II [16]. EP25 and EP21, in which these
residues are removed, act as slow-binding inhibitor. For complete
inhibition, they required 20 min of pre-incubation with thrombin.
Since exosite-II is located about 10 A ˚ away from the active site
[33], we extended EP21 by three residues at the N-terminal to
include one of the two acidic residues,
VAsp5, in DV24. The non-
linear progress curves of thrombin inhibition by EP21 (character-
istic of slow binding inhibitors), changed to linear progress curves
of inhibition by DV24 (characteristic of fast binding inhibitor)
(Figure S6). The IC50 and Ki values of DV24 are identical to those
of s-variegin (Table 2). Like for s-variegin, a fast binding inhibitor,
the IC50 of DV24 increases with pre-incubation due to the
cleavage by thrombin. Thus, DV24 is eight residues shorter than s-
variegin but retains fast-binding kinetics and potency.
(a) Optimization of thrombin:variegin interactions. As
observed in the thrombin:s-variegin structure,
VHis12 binds
to the prime subsite, with its side chain nitrogen forming
hydrogen bond with
TSer195 and disrupting the charge
relay system of the thrombin catalytic triad. In order to
verify the significance of
VHis12, two variants were
synthesized by replacing this residue with Ala. The two
Figure 3. Interactions between thrombin and s-variegin. (A) Prime subsites interactions between thrombin and s-variegin (residues P29 to P59)
are shown. Density for s-variegin P19
VMet11 cannot be traced in the structure. Thrombin S29 subsite is colored in red, S39 subsite in cyan, S49 subsite
in pink and S59 subsite in green. (B) Thrombin residues that interfaced with s-variegin are colored according to their positions: catalytic pocket (blue):
THis57,
TCys58,
TCys191,
TGlu192,
TGly193,
TSer195; 60-loop (red):
TTrp60D and
TLys60F; autolysis loop (cyan):
TTrp141,
TGly142,
TAsn143,
TThr147 and
TGln151; 34-loop (brown):
TPhe34,
TArg35,
TGln38 and
TGlu39; 70-loop (green):
TArg73,
TThr74,
TArg75,
TTyr76 and
TArg77A; bottom of the cleft
(orange):
TMet32,
TLeu40,
TLeu41,
TCys42,
TLeu65,
TArg67,
TLys81,
TIle82,
TMet84 and
TLys110. Sticks model of s-variegin is shown in pink. (C) All but
four residues (
VPhe18,
VAla22,
VGlu25 and
VLeu28, white) on s-variegin have their side chains buried in the interface with thrombin.
doi:10.1371/journal.pone.0026367.g003
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26367Figure 4. Electrostatic interactions in thrombin:s-variegin structure. (A) s-Variegin and hirulog-3 have distinct ion pairs formed with exosite-I
of thrombin despite high sequence identity. A salt bridge (3.84 A ˚) between
VGlu26 (pink) and
TArg77A (yellow) is absent in hirulog-3 as
TArg77A
(cyan) points away from the inhibitor. Weak salt bridge (4.64 A ˚) is also likely between
VGlu21 (pink) and
TArg75 (yellow) rotated 90.5u about Cb
compared to
TArg75 in hirulog-3 bound thrombin (cyan) to facilitate interaction with
VGlu21 (pink). Electron density maps of residues involved are
shown in Figure S2A. (B) The strong ion pair (Asp11:
TArg73, 2.92 A ˚) in thrombin:hirulog-3 structure is absent in thrombin:s-variegin structure since
VAsp19 (pink) pointed to an opposite direction compared to the analogous hirulog-3 Asp11 (blue) due to a kink in s-variegin backbone (pink).
Electron density maps of residues involved are shown in Figure S2B. (C) The presence of a
VPro16-
VPro17 (green) in s-variegin resulted in the kink.
Superimposition of s-variegin (pink, only Ca positions traced) and hirulog-3 (blue, only Ca positions traced) based on their thrombin structures
showed displacement of
VPhe18 and
VAsp19 from their corresponding residues Gly10 and Asp11 of hirulog-3 by 3.11 A ˚ and 0.79 A ˚ (measured by Ca
positions), respectively. As a result, the distance between
TArg73 and
VAsp19 charges are 5.83 A ˚, rendering electrostatic interactions impossible.
doi:10.1371/journal.pone.0026367.g004
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Name Sequence
Pre-
incubation
tine (min) IC50 (nM) Ki (nM) Mechanism
Plots
shown in
figure
s-variegin SDQGDVAEPKMHKTAPPFDFEAIPEEYLDDES 0 8.2560.45 0.31860.020 Fast, tight-binding,
competitive
Published
[17]
20 10.460.3
EP25 SDQGDVAEPKMHKTAPPFDFEAIPEEYLDDES 0 173626 0.36560.109 Slow, tight-binding,
competitive
S3
20 13.160.7
MH22 SDQGDVAEPKMHKTAPPFDFEAIPEEYLDDES 0 11.560.7 14.160.3 Fast, tight-binding,
noncompetitive
Published
[17]
20 12.361.9
Hirulog-1 DFPRPGGGGNGDFEEIPEEYL 0 72.663.9 2.9460.12 Fast, tight-binding,
competitive
Published
[17]
10 102613
EP21 SDQGDVAEPKMHKTAPPFDFEAIPEEYLDDES 0 17767 0.31560.024 Slow, tight-binding,
competitive
S4
20 16.262.9
MH18 SDQGDVAEPKMHKTAPPFDFEAIPEEYLDDES 0 10.961.2 14.963.5 Fast, tight-binding,
noncompetitive
S5
20 11.761.9
DV24 SDQGDVAEPKMHKTAPPFDFEAIPEEYLDDES 0 7.4960.28 0.30660.029 Fast, tight-binding,
competitive
S7
20 10.160.6
DV24H12A SDQGDVAEPKMAKTAPPFDFEAIPEEYLDDES 0 48.2612.4 3.2360.48 Fast, tight-binding,
competitive
S8
20 141611
MH18H12A SDQGDVAEPKMAKTAPPFDFEAIPEEYLDDES 0 328623 32968 Fast, tight-binding,
noncompetitive
S9
20 343646
DV24K10R SDQGDVAEPRMHKTAPPFDFEAIPEEYLDDES 0 6.9860.76 0.25960.015 Fast, tight-binding,
competitive
S10
20 12.060.4
DV23 SDQGDVAEPKMHKTAPPFDFEAIPEEYLDDES 0 45.461.6 2.1960.23 Fast, tight-binding,
competitive
S11
20 77.866.1
DV23K10R SDQGDVAEPRMHKTAPPFDFEAIPEEYLDDES 0 12.961.0 0.60060.010 Fast, tight-binding,
competitive
S12
20 10261
EP25A22E SDQGDVAEPKMHKTAPPFDFEEIPEEYLDDES 0 124623 0.31160.070 Slow, tight-binding,
competitive
S13
20 13.562.1
MH22A22E SDQGDVAEPKMHKTAPPFDFEEIPEEYLDDES 0 13.660.5 15.161.0 Fast, tight-binding,
noncompetitive
S14
20 15.660.4
DV24Y
phos SDQGDVAEPKMHKTAPPFDFEAIPEEY
"LDDE 0 8.6760.45 0.32760.032 Fast, tight-binding,
competitive
S15
20 12.461.2
DV24K10RY
phos SDQGDVAEPRMHKTAPPFDFEAIPEEY
"LDDES 0 4.6460.78 0.15060.018 Fast, tight-binding,
competitive
S16
20 7.8061.80
DV24Y
sulf SDQGDVAEPKMHKTAPPFDFEAIPEEY*LDDE 0 1.6660.18 0.056060.0180 Fast, tight-binding,
competitive
S17
20 2.0260.29
DV24K10RY
sulf SDQGDVAEPRMHKTAPPFDFEAIPEEY*LDDE 0 1.3960.17 0.042060.0061 Fast, tight-binding,
competitive
S18
20 1.6660.21
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sequences of DV24 and MH18, repectively and represent
the minimal interacting sequences of variegin and cleaved
fragment. Both peptides lose their inhibitory potency
significantly. IC50 (,6 fold) and Ki (,10 fold) values of
DV24H12A increase when compared to DV24. Pre-
incubation of DV24H12A with thrombin also causes a
larger increase in IC50 (,3 fold in 20 min) when compared
to DV24 (,2 fold) (Table 2).
MH18H12A shows a more drastic increase in IC50 (,30 fold)
and Ki (,22 fold) values, compared to MH18 (Table 2). Maximum
inhibition by MH18H12A appears to saturate near 80% (highest
concentration used is 30 mM), implying that the peptide is unable
to completely inhibit thrombin. Thus, the single mutation of
VHis12 to Ala significantly affects the inhibitory action of the
peptide, ascertaining the importance of
VHis12, as observed in the
structure of thrombin:s-variegin complex. However, the activity is
not completely abolished possibly due to other interactions in the
prime subsites retained in these alanine mutants.
One striking difference between variegin and other thrombin
substrates/inhibitors is the presence of Lys, instead of Arg, at P1.
Typically, P1 Lys interacts with
TAsp189 through a water
molecule, resulting in reduced affinity and specificity [34,35].
Therefore, using DV24 as a template sequence, the P1 residue
(
VLys10) was replaced by Arg in DV24K10R. The peptide has
marginally improved IC50 and Ki values, when compared to DV24
(Table 2). Substitution of P1 Lys by Arg appears to accelerate the
cleavage, as shown by the higher IC50 after 20 min pre-incubation,
when compared to DV24 (Table 2).
As in hirulogs, hirugen and hirudin, the phenyl group of
VPhe20
interacts with
TPhe34 through p-stacking. In s-variegin, there are
nine residues between this
VPhe20 and the P1 residue,
V(
11MHKTAPPFD
19), unlike in hirulog-1/-3, which has only eight
residues (
4PGGGGNGD
11).
VPro16 and
VPro17 induce a kink in the
s-variegin backbone, causing a slight bend upwards, away from
thrombin (Figure 4B). This, in turn, causes displacement of
VPhe18
and
VAsp19 by about 3.11 A ˚ and 0.79 A ˚ (based on Ca positions),
respectively against their analogs in hirulog-3 (Gly10 and Asp11).
Crucially, Asp11 of hirulog-3 makes an ion pair with
TArg73, while
analogous
VAsp19 does not (Figure 4B). In fact, the
VAsp19 side
chain points in the opposite direction (towards solvent), with a 5.83 A ˚
distance between
VAsp19 and
TArg73 (Figure 4C). To remove the
kink in the backbone, reposition
VAsp19 and create the ionic
interaction,
VPro16 was deleted in variants DV23 and DV23K10R.
However, DV23 shows an average of ,7 fold reduction in IC50 when
compared to DV24 (Table 2). The other variant, DV23K10R,i sa l s o
less active when compared to DV24K10R, albeit to a lesser extent
(Table 2). IC50 values of both DV23 and DV23K10R significantly
increased upon pre-incubation, implies that the cleaved products no
longer potently inhibits thrombin (Table 2). In addition, the peptide
with Arg at P1(DV23K10R) is hydrolyzed by thrombinat a faster rate
than the peptide with Lys at P1 (DV23) judging from the more rapid
increase of IC50 values with pre-incubation (Table 2). Thus, the
deletion of
VPro16 has an adverse effect on the activities of both the
intact and cleaved peptides. This deletion probably compromises the
interactions of P9 residues with the prime subsites, owing to their
proximity to
VPro16.
In hirudin,
HGlu58 makes an ion-pair with
TArg77A [3,32].
However, in variegin, this Glu is replaced by
VAla22 and its side
chain is solvent exposed (Figure 3C).
VAla22 was replaced by Glu
in variants EP25A22E and MH22A22E. The four C-terminal
residues were retained in these variants to maintain the original
micro-environment near the C-terminus. IC50 and Ki values of
EP25A22E and MH22A22E are similar to their templates (EP25
and MH22, respectively) (Table 2). Thus, the replacement of
VAla22 by Glu does not enhance the activity of variegin.
Desulfation of Tyr63 in hirudin or hirugen is known to reduce
their affinities to thrombin by about 10 fold [36–38]. Interestingly,
the analogous residue in native variegin,
VTyr27, is not sulfated.
We postulated that modification of
VTyr27 could also increase its
binding affinity towards thrombin. Considering the similarity of
phosphate and sulfate moieties (similar size and overall negative
charge), phosphotyrosine and sulfotyrosine residues were incorpo-
rated to design new variants.
Onephosphotyrosineresiduewasadded to DV24andDV24K10R
to produce the variants DV24Y
phos and DV24K10RY
phos,r e s p e c t i v e l y .
DV24Y
phos is marginally less active than DV24, whereas
DV24K10RY
phos has slightly improved activity (Table 2).
Similarly, a sulfotyrosine residue was incorporated in three new
variants, DV24Y
sulf,D V 2 4 K10RY
sulf and MH18Y
sulf. DV24Y
sulf and
DV24K10RY
sulf show an average ,5f o l di n c r e a s ei nIC50 and Kivalues
when compared to the respective non-sulfated variants, DV24 and
DV24K10R, respectively (Table 2). MH18Y
sulf also has improved
activity when compared to MH18 (Table 2). It is very likely that the
presence of sulfo-Tyr27 and the truncation of extra residues in variegin
variants cause a rearrangement of the C-terminal conformation to
mimic the hirugen/hirudin C-termini. Strong affinities are obtained in
these variants through optimization of C-terminal interactions.
Figure 5 shows the plot of Ki values of all peptides (including
hirulog-1/bivalirudin). Affinity of DV24K10RY
sulf for thrombin
(Ki=42.066.1 pM) is ,70 fold stronger than that of hirulog-1/
bivalirudin (Ki=2.9460.12 nM). Based on the derived structure-
activity relationships, we have designed a shorter (24-mer
DV24K10RY
sulf against 32-mer s-variegin) yet more potent
thrombin inhibitor (Ki of 42 pM compared to 318 pM).
In vivo antithrombotic effects of the peptides
Five inhibitors were selected as representatives to test for their
antithrombotic effects in vivo using the zebrafish larvae venous
thrombosis model: (1) s-variegin, the full-length variegin, a fast
and tight-binding competitive inhibitor; (2) EP25, without seven
Name Sequence
Pre-
incubation
tine (min) IC50 (nM) Ki (nM) Mechanism
Plots
shown in
figure
MH18Y
sulf SDQGDVAEPKMHKTAPPFDFEAIPEEY*LDDES 0 1.2660.18 1.2560.18 Fast, tight-binding,
noncompetitive
S19
20 1.1760.14
Y
": phosphotyrosine; Y*: sulfotyrosine.
doi:10.1371/journal.pone.0026367.t002
Table 2. Cont.
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slow and tight-binding competitive inhibitor; (3) MH22, the
cleaved product that is a fast and tight-binding, noncompetitive
inhibitor; (4) DV24K10RY
sulf, the most potent in vitro inhibitor
that is a fast and tight-binding competitive inhibitor and (5)
hirulog-1/bivalirudin, a fast, tight-binding, competitive inhibitor
currently in clinical use. Hirulog-1/bivalirudin was used as a
positive control.
All five peptides were injected into the zebrafish larvae
circulation through the posterior (caudal) cardinal vein at a single
dose (500 mM, 10 nl). The antithrombotic effects of the peptides
were measured as the delay in time-to-occlusion (TTO) of the
caudal vein after laser ablation (Figure 6). Overall, other than
EP25, the antithrombotic effects of the peptides correlated well
with their affinities for thrombin. Thus, the slow-binding
inhibitory mode (EP25) is not desirable for in vivo efficacy while
both fast, competitive (s-variegin, DV24K10RY
sulf and hirulog-1/
bivalirudin) and fast, noncompetitive (MH22) inhibitors are
effective. Our results are consistent with similar observations
reported earlier about the importance of rapid thrombin inhibition
for efficacious antithrombotic agents [39].
Discussion
Variegin belongs to a unique class of thrombin inhibitors that
have potential as antithrombotic agents [16,17]. We solved the
structure of thrombin:s-variegin complex at 2.4 A ˚ resolution.
Despite the use of full-length s-variegin for co-crystallization, only
the density of its C-terminal fragment was observed. The cleaved
fragment (equivalent to MH22) stays bound tightly to the prime
subsites and exosite-I, exhibiting prolonged inhibitory action
(.18 h) [17].
Active site inhibitors of thrombin typically target the non-prime
subsites, hindering the access of substrates (including the
chromogenic substrate S2238 used in this study) to the catalytic
residues [29,31,40]. The full-length variegin also acts in a similar
way and competitively inhibits the thrombin active site [16]. The
present thrombin:s-variegin structure reveals two exciting features:
(1) the novel mechanism of thrombin inhibition through disruption
of the charge relay system, and (2) the binding with thrombin
prime subsites. The cleaved product (MH22) still retains inhibition
through this novel mechanism, as observed in the structure. The
lack of overlaps in MH22 and S2238 binding sites (non-prime and
S19 subsites), demonstrates the feasibility of simultaneous binding
of S2238 and MH22 to thrombin with no changes in affinities of
either (Figure S20). The binding of substrate (S2238) to the
thrombin active site becomes non-productive due to the disruption
of the charge relay system by MH22 (Figure 2). We also speculate
that the binding of variegin/MH22 to the prime subsites induces
minor structural changes that may interfere with the entry of
S2238 or exit of products from the active site without affecting the
strength of substrate binding. Thus the structure explains the
classical noncompetitive inhibition by MH22.
The interaction between the variegin and thrombin prime
subsites is equally interesting. The S9 subsites’ interactions between
the inhibitors and protease are important for binding [41]. A
systematic probing of thrombin S9 subsites with ‘methyl scan’ also
has demonstrated the potential for targeting prime subsites in the
design of inhibitors [42]. However, unlike variegin, other naturally
occurring thrombin inhibitors, including hirudin [31], rhodniin
[43], ornithodorin [44] and boophilin [45], are not inserted into
the canyon-like cleft (the prime subsites) connecting the active site
and exosite-I. Similarly, the previous structures of thrombin, in
Figure 5. Ki values of all peptides (including hirulog-1/bivalirudin). Peptides are grouped according to their mechanism of actions. All
competitive inhibitors (fast or slow) have higher affinities to thrombin compared to hirulog-1/bivalirudin. The most potent variant DV24K10RY
sulf is
about 70-fold stronger. Even their cleavage products (non-competitive inhibitors) are potent inhibitor, with one of them, MH18Y
sulf, binds to
thrombin approximately 2-fold tighter than hirulog-1/bivalirudin.
doi:10.1371/journal.pone.0026367.g005
A Novel Mechanism of Thrombin Inhibition
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e26367complex with other macromolecular substrates [46–50], typically
lack complete details in the interactions within this region. Thus,
when compared to the non-prime subsites, understanding of the
binding preferences for the thrombin prime subsites (especially S29
and beyond) is much less complete [1]. Recently, the structure of a
PAR1 fragment in complex with an inactive thrombin mutant
TSer195A was published [51]. This structure provided new details
on the interaction within the prime subsites. However, there is
considerable disorderliness in the PAR1 molecule binding to this
region. As a result, it was suggested that the prime subsites binding
segment of PAR1 snaps away from thrombin upon cleavage [51].
In the case of substrates, such a mechanism is probably
advantageous to ensure a faster turnover. However, inhibitors
are developed to bind to thrombin as tight and long as possible. In
this specific case, variegin has evolved to bind to the thrombin
prime subsites and thus the structure of the thrombin:s-variegin
complex provides a unique opportunity to understand the
interaction of this inhibitor with the thrombin prime subsites
which is of extreme importance to the design of more effective
inhibitors.
In hirulog-1/bivalirudin, the glycyl linkers connect the active
site and exosite-I binding moieties without displaying specific
interactions with the thrombin prime subsites. As a result, this
segment is disordered in the crystal structure [4] and the activity is
rapidly lost after cleavage by thrombin [17,52]. When anchored
by a non-hydrolyzable active site binding moiety and an exosite-I
binding segment, the non-specific linker is forced to fit into the
canyon-like cleft in the prime subsites, as seen in hirulog-3 [22]
and P498 [40]. In these cases, the S9 subsite interactions are sub-
optimal due to the lack of specific side chain interactions. As a
result, extensive and lengthy optimizations, through synthetic
chemistry using multiple and unnatural amino acids, were
necessary to produce inhibitors with enhanced binding to the
prime subsites [42,53,54]. In contrast, tight binding of s-variegin to
the prime subsites is achieved through specific interactions
involving the side chains of natural amino acids. Thus the
thrombin-variegin complex provides important and detailed
structural information for inhibition of the thrombin prime
subsites. This structural observation for the prime subsites binding
in variegin is also consistent with the structure-function data
presented here and elsewhere [16,17]. The firm insertion of
variegin peptides into the cleft in an extended conformation is
probably the simplest structure needed to achieve strongest and
instantaneous binding to the thrombin catalytic pocket, prime
subsites and exosite-I. This ‘minimalistic’ approach in nature
(ticks) confers an advantage of minimum energy expenditure
(protein synthesis) for maximum outcome (potent inhibition of
coagulation enzymes to facilitate blood-feeding).
Based on the thrombin:s-variegin structure and other available
information, we performed targeted structure-function relation-
ship studies on variegin. Substitution of P1 Lys by Arg is reported
to increase affinity for thrombin by ,10 fold through a better fit to
the S1 subsite [2,35]. However, our results show that the
improvement in affinity by this substitution varies. In DV24,
DV24Y
sulf and DV24Y
phos, the effects of substitution are less than 2
fold. It is likely that the extensive interactions between the s-
variegin P9 residues and thrombin S9 subsite compensate for the
loose fitting of P1 Lys. In contrast, DV23/DV23K10R-thrombin
interactions around the prime subsites are likely to be disturbed
due to the deletion of Pro16 (DV23 Ki is ,7 fold higher than
DV24). In this situation, P1 Arg facilitates stronger binding of the
V(
5DVAEPR
10) sequence to the active site compared to P1 Lys,
which is reflected by the higher gain in affinity (,4 fold decrease in
Ki). These results further support the importance of prime subsite
interactions.
We have also shown that addition of three residues at the N-
terminus of the slow-binding inhibitor EP21 changes it to a fast-
binding inhibitor. Thus, the prime subsites anchoring effect
(discussed above) mainly drives affinity for the thrombin active site,
while the N-terminal steering effect is needed for proper pre-
orientation of this segment. Hence, the P1 to P3 residues of s-
variegin are inserted rapidly into the thrombin active site, assisted
by prime subsites targeting and the N-terminal negative charge.
Once in the acidic S1 pocket, P1 Lys/Arg interacts with
TAsp189
Figure 6. In vivo antithrombotic effects of peptides. Zebrafish 4 days post-fertilization larvae were injected with 10 nl of different peptides at
500 mM or 10 nl of PBS as control. TTO for larvae injected with PBS, hirulog-1/bivalirudin, s-variegin, EP25 and MH22 are 19.063.2 s, 45.065.5 s,
120.867.4 s, 22.566.2 s and 33.362.9 s, respectively. Within 150 s, no thrombus was formed in larvae injected with DV24K10RY
sulf. With the
exception of the slow binding inhibitor EP25, the abilities of the peptides to prolong TTO correlate with their in vitro Ki (n=4, error bars represent
S.D.).
doi:10.1371/journal.pone.0026367.g006
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a less stringent requirement for the P1 residue that can be
exploited for the design of new specific thrombin inhibitors. In
addition to the prime subsite interaction,
VHis12 draws
TSer192
out of position and affects the geometry of the crucial catalytic
residue as well as interfering in the charge relay system. The result
is decreased catalytic efficiency. Such a design may be exploited in
the development of inhibitors for other serine proteases.
The new variegin variants cover a big range of potency, speed of
onset and kinetic parameters, showing the potential to ‘tune’
variegin to provide different therapeutic properties. The unique
ability of variegin to potently inhibit thrombin (initially compet-
itive, subsequently noncompetitive) for a long duration represents
a new approach to anticoagulation when compared to other direct
thrombin inhibitors on the market. Variegin and some of its
variants inhibit thrombin potently with low Ki (between 0.04 to
0.4 nM). Their affinities for thrombin are stronger than hirulog-1/
bivalirudin (Ki=2.3 nM) [55], argatroban (Ki=3.2 nM) [56] and
dabigatran (Ki=4.5 nM) [57] but weaker than hirudin
(Ki=0.2 pM) [36]. While weaker affinities may translate to lower
efficacy and increased probability of side effects, the almost
irreversible binding of hirudin to thrombin (Ki=0.2 pM) may be
responsible for an increased risk of major bleeding when compared
to unfractionated heparin [58]. Thus, in terms of affinity for
thrombin, variegin may represent a good balance between potency
and safety. The prolonged action of variegin might also allow
single dose administration instead of continuous infusion (as in the
case of hirulog-1/bivalirudin) [11] especially in short procedures
such as percutaneous coronary intervention. We also have
preliminary data showing the possibility of using protamine as
antidote for variegin. Overall, variegin (with its variants) represents
a fine balance between hirudin and hirulog-1/bivalirudin for most
of their properties (Ki, size, duration of action etc.). At this point,
the strong in vivo antithrombotic effects support the continual
development of variegin and its variants as potential and improved
anticoagulants.
Supporting Information
Figure S1 Conformation of s-variegin C-terminus. s-
Variegin C-terminus (pink) has a vastly different conformation
compared to hirulog-1, hirulog-3, hirugen and sulfo-hirudin: (A)
Residues PEEYL in hirulog-1 (red) are disordered and missing
from the structure. (B) Residues PEEYL in hirulog-3 (blue) form a
310 helix turn. (C) These residues in hirugen (green), with sulfated
tyrosine, also form a 310 helix turn. (D) Other than Tyr-sulfation,
sulfo-hirudin (cyan) C-terminus has an extra Gln, forms a full a-
helical turn.
(TIF)
Figure S2 Electrostatic interactions in thrombin:s-var-
iegin structure. (A) Figure shows the electron density map (2Fo-
Fc, 0.9s) of residues described in Figure 4A in the main
manuscript. Thrombin is colored yellow and s-variegin is colored
pink. Map for thrombin colored in light cyan and map for s-
variegin colored in gray. Residues involved in forming salt bridges
are labeled. (B) Figure shows the electron density map (2Fo-Fc,
0.9s) of residues described in Figure 4B in the main manuscript.
Thrombin is colored yellow and s-variegin is colored pink. Map
for thrombin colored in light cyan and map for s-variegin colored
in gray.
(TIF)
Figure S3 Variegin variant EP25 (slow binding, com-
petitive inhibitor). (A) Dose response curves of thrombin
(1.65 nM) inhibited by EP25 (0.1 nM, 0.3 nM, 1 nM, 3 nM,
10 nM, 30 nM, 100 nM, 300 nM, 1000 nM, 3000 nM) in S2238
(100 mM) showed a left shift with increased pre-incubation time
due to slow binding. IC50 are 173626 nM without pre-incubation
(& solid line) and 13.160.7 nM with 20 min pre-incubation (#
dotted line) (n=3, error bars represent S.D.). (B) Progress curves
(not shown) of thrombin (0.8 nM) inhibited by EP25 (9.4 nM,
12.5 nM, 18.8 nM, 25 nM, 37.5 nM, 50 nM, 75 nM and
100 nM) in S2238 (100 mM) were fitted to equation (6) describing
a slow binding inhibitor to obtain a k for each concentrations of
EP25. Plot of k against EP25 concentrations (& solid line) is
hyperbolic and fitted to equation (7) producing Ki9 of
0.88260.128 nM, representing the dissociation constant of initial
collision complex EI (scheme 1). Ki calculated from equation (8)
is 0.36560.109 nM (n=3, error bars represent S.D.).
(TIF)
Figure S4 Variegin variant EP21 (slow binding, com-
petitive inhibitor). (A) Dose response curves of thrombin
(1.65 nM) inhibited by EP21 (0.3 nM, 1 nM, 3 nM, 10 nM,
30 nM, 100 nM, 300 nM, 1000 nM, 3000 nM and 10000 nM) in
S2238 (100 mM) showed a left shift with increased pre-incubation
time due to slow binding. IC50 are 17767 nM without pre-
incubation (& solid line) and 16.262.9 nM with 20 min pre-
incubation (# dotted line) (n=3, error bars represent S.D.). (B)
Progress curves (Figure S4) of thrombin (0.8 nM) inhibited by
EP21 (18.8 nM, 25 nM, 37.5 nM, 50 nM, 75 nM, 100 nM and
150 nM) in S2238 (100 mM) were fitted to equation (6) describing
a slow binding inhibitor to obtain a k for each concentrations of
EP21. Plot of k against EP21 concentrations (& solid line) is
hyperbolic and fitted to equation (7) producing Ki9 of
1.6660.36 nM, representing the dissociation constant of initial
collision complex EI (scheme 1). Ki calculated from equation (8)
is 0.31560.024 nM (n=3, error bars represent S.D.).
(TIF)
Figure S5 Variegin variant MH18 (fast, tight-binding,
noncompetitive inhibitor). (A) Dose response curves of
thrombin inhibition (1.65 nM) by MH18 (0.1 nM, 0.3 nM,
1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1000 nM,
3000 nM and 10000 nM) in S2238 (100 mM) are independent of
pre-incubation time. IC50 are 10.961.2 nM without pre-incuba-
tion (& solid line) and 11.761.9 nM with 20 min pre-incubation
(# dotted line) (n=3, error bars represent S.D.). (B) Thrombin
(1.65 nM) inhibition was tested with MH18 (0.39 nM, 0.78 nM,
1.56 nM, 3.13 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM, 100 nM
and 200 nM) in S2238 (100 mM) (& solid line). Apparent
inhibition constant Ki9 obtained by fitting data to equation (2),
describing fast and tight-binding inhibitor, is 14.963.5 nM. Ki
calculated from equations (4) and (5), describing noncompetitive
inhibitors, is 14.963.5 nM (n=3, error bars represent S.D.).
(TIF)
Figure S6 Progress curves of thrombin inhibitied by
EP21 and DV24. (A) Progress curves of thrombin (0.8 nM)
inhibited by different concentrations of EP21 using S2238
(100 mM) as substrate, without pre-incubation of thrombin and
EP21. The non-linear behavior of the curves at the beginning of
the reactions and an improved IC50 with pre-incubation (Figure
S4) suggested equilibrium of inhibition was achieved slowly,
characteristic of slow-binding inhibitors. (B) Progress curves of
thrombin (1.65 nM) inhibited by different concentrations of
DV24: 0 nM (&), 0.1 nM (%), 0.3 nM (N), 1 nM (#), 3 nM
(m), 10 nM (n), 30 nM (.), 100 nM (,), 300 nM (X) and
1000 nM (e) using S2238 (100 mM) as substrate, without pre-
incubation of thrombin and DV24. The linear curves indicate the
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and DV24, characteristic of fast-binding inhibitors.
(TIF)
Figure S7 Variegin variant DV24 (fast, tight-binding,
competitive inhibitor). (A) Dose-response curves of thrombin
(1.65 nM) inhibited by DV24 (0.1 nM, 0.3 nM, 1 nM, 3 nM,
10 nM, 30 nM, 100 nM, 300 nM, 1000 nM and 3000 nM) in
S2238 (100 mM) showed a right shift with increased pre-
incubation time due to cleavage. IC50 are 7.4960.28 nM without
pre-incubation (& solid line) and 10.160.6 nM with 20 min pre-
incubation (# dotted line) (n=3, error bars represent S.D.). (B)
Thrombin (1.65 nM) inhibition was tested with DV24 (0.39 nM,
0.78 nM, 1.56 nM, 3.13 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM,
100 nM and 200 nM) in S2238 (100 mM) (& solid line). Apparent
inhibition constant Ki9 obtained by fitting data to equation (2),
describing fast and tight-binding inhibitor, is 9.7460.91 nM. Ki
calculated from equation (3), describing competitive inhibitors, is
0.30660.029 nM (n=3, error bars represent S.D.).
(TIF)
Figure S8 Variegin variant DV24H12A (fast, tight-bind-
ing, competitive inhibitor). (A) Dose-response curves of
thrombin (1.65 nM) inhibited by DV24H12A (0.001 mM,
0.003 mM, 0.01 mM, 0.03 mM, 0.3 mM, 1 mM, 3 mM, 10 mM
and 30 mM) in S2238 (100 mM) showed a right shift with increased
pre-incubation time due to cleavage. IC50 are 48.2612.4 nM
without pre-incubation (& solid line) and 141611 nM with
20 min pre-incubation (# dotted line) (n=3, error bars represent
S.D.). (B) Thrombin (1.65 nM) inhibition was tested with
DV24H12A (1.95 nM, 3.91 nM, 7.81 nM, 15.6 nM, 31.3 nM,
62.5 nM, 125 nM, 250 nM, 500 nM and 1000 nM) in S2238
(100 mM) (& solid line). Apparent inhibition constant Ki9 obtained
by fitting data to equation (2), describing fast and tight-binding
inhibitor, is 103615 nM. Ki calculated from equation (3),
describing competitive inhibitors, is 3.2360.48 nM (n=3, error
bars represent S.D.).
(TIF)
Figure S9 Variegin variant MH18H12A (fast, noncom-
petitive inhibitor). (A) Dose-response curves of thrombin
(1.65 nM) inhibition by MH18H12A (0.001 mM, 0.003 mM,
0.01 mM, 0.03 mM, 0.3 mM, 1 mM, 3 mM, 10 mM and 30 mM)
in S2238 (100 mM) are independent of pre-incubation time. IC50
are 328623 nM without pre-incubation (& solid line) and
343646 nM with 20 min pre-incubation (n=3, error bars
represent S.D.). (B) Thrombin (1.65 nM) inhibition was tested
with 1 mM MH18H12A (# dotted line) in S2238 (4.69 mM,
9.34 mM, 18.8 mM, 37.5 mM, 75 mM, 150 mM and 300 mM) and
without the inhibitor (& solid line) in S2238 (3.13 mM, 6.25 mM,
12.5 mM, 25 mM, 50 mM, 100 mM, 200 mM). MH18H12A is
unable to inhibit thrombin at equimolar concentration, hence is
not considered as tight-binding inhibitor. The double-reciprocal
plot showed noncompetitive inhibition and Ki is 32968n M( n=3 ,
error bars represent S.D.).
(TIF)
Figure S10 Variegin variant DV24K10R (fast, tight-
binding, competitive inhibitor). (A) Dose-response curves
of thrombin (1.65 nM) inhibited by DV24K10R (0.1 nM, 0.3 nM,
1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1000 nM and
3000 nM) in S2238 (100 mM) showed a right shift with increased
pre-incubation time due to cleavage. IC50 are 6.9860.76 nM
without pre-incubation (& solid line) and 12.060.4 nM with
20 min pre-incubation (# dotted line) (n=3, error bars represent
S.D.). (B) Thrombin (1.65 nM) inhibition was tested with
DV24K10R (0.39 nM, 0.78 nM, 1.56 nM, 3.13 nM, 6.25 nM,
12.5 nM, 25 nM, 50 nM, 100 nM and 200 nM) in S2238
(100 mM) (& solid line). Apparent inhibition constant Ki9 obtained
by fitting data to equation (2), describing fast and tight-binding
inhibitor, is 8.2760.85 nM. Ki calculated from equation (3),
describing competitive inhibitors, is 0.25960.015 nM (n=3, error
bars represent S.D.).
(TIF)
Figure S11 Variegin variant DV23 (fast, tight-binding,
competitive inhibitor). (A) Dose-response curves of thrombin
(1.65 nM) inhibited by DV23 (0.1 nM, 0.3 nM, 1 nM, 3 nM,
10 nM, 30 nM, 100 nM, 300 nM, 1000 nM and 3000 nM) in
S2238 (100 mM) showed a right shift with increased pre-
incubation time due to cleavage. IC50 are 45.461.6 nM without
pre-incubation (& solid line) and 77.866.1 nM with 20 min pre-
incubation (# dotted line) (n=3, error bars represent S.D.). (B)
Thrombin (1.65 nM) inhibition was tested with DV23 (3.91 nM,
7.81 nM, 15.6 nM, 31.3 nM, 62.5 nM, 125 nM, 250 nM and
500 nM) S2238 (100 mM) (& solid line). Apparent inhibition
constant Ki9 obtained by fitting data to equation (2), describing fast
and tight-binding inhibitor, is 69.667.8 nM. Ki calculated from
equation (3), describing competitive inhibitors, is 2.1960.23 nM
(n=3, error bars represent S.D.).
(TIF)
Figure S12 Variegin variant DV23K10R (fast, tight-
binding, competitive inhibitor). (A) Dose-response curves
of thrombin (1.65 nM) inhibited by DV23K10R (0.1 nM, 0.3 nM,
1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1000 nM and
3000 nM) in S2238 (100 mM) showed a strong right shift with
increased pre-incubation time due to cleavage. IC50 are
12.961.0 nM without pre-incubation (& solid line) and
10261 nM with 20 min pre-incubation (# dotted line) (n=3,
error bars represent S.D.). (B) Thrombin (1.65 nM) inhibition was
tested with DV23K10R (3.91 nM, 7.81 nM, 15.6 nM, 31.3 nM,
62.5 nM, 125 nM, 250 nM and 500 nM) in S2238 (100 mM) (&
solid line). Apparent inhibition constant Ki9 obtained by fitting
data to equation (2), describing fast and tight-binding inhibitor, is
19.161.9 nM. Ki calculated from equation (3), describing
competitive inhibitors, is 0.60060.010 nM (n=3, error bar
represents S.D.).
(TIF)
Figure S13 Variegin variant EP25A22E (slow binding,
competitive inhibitor). (A) Dose-response curves of thrombin
(1.65 nM) inhibited by EP25A22E (0.1 nM, 0.3 nM, 1 nM, 3 nM,
10 nM, 30 nM, 100 nM, 300 nM, 1000 nM and 3000 nM) in
S2238 (100 mM) showed a left shift due to slow binding. IC50 are
124623 nM without pre-incubation (& solid line) and
13.562.1 nM with 20 min pre-incubation (# dotted line) (n=3,
error bars represent S.D.). (B) Progress curves (not shown) of
thrombin (0.8 nM) inhibited by EP25A22E (9.38 nM, 12.5 nM,
18.8 nM, 25 nM, 37.5 nM, 50 nM, 75 nM, 100 nM, 150 nM,
200 nM and 300 nM) in S2238 (100 mM) were fitted to equation
(6) describing a slow binding inhibitor to obtain a k for each
concentrations of EP25A22E. Plot of k against EP25A22E
concentrations (& solid line) is hyperbolic and was fitted to
equation (7) producing Ki9 of 1.0260.060 nM, representing the
dissociation constant of initial collision complex EI (scheme 1). Ki
calculated from equation (8) is 0.31160.070 nM (n=3, error bars
represent S.D.).
(TIF)
Figure S14 Variegin variant MH22A22E (fast, tight-
binding, noncompetitive inhibitor). (A) Dose-response
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0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM,
1000 nM and 3000 nM) in S2238 (100 mM) are independent of
pre-incubation time. IC50 are 13.6260.45 nM without pre-
incubation (& solid line) and 15.660.4 nM with 20 min pre-
incubation (# dotted line) (n=3, error bars represent S.D.). (B)
Thrombin (1.65 nM) inhibition was tested with MH22A22E
(0.39 nM, 0.78 nM, 1.56 nM, 3.13 nM, 6.25 nM, 12.5 nM,
25 nM, 50 nM, 100 nM and 200 nM) in S2238 (100 mM) (&
solid line). Apparent inhibition constant Ki9 obtained by fitting
data to equation (2), describing fast and tight-binding inhibitor, is
15.161.0 nM. Ki calculated from equations (4) and (5), describing
noncompetitive inhibitors, is 15.161.0 nM (n=3, error bars
represent S.D.).
(TIF)
Figure S15 Variegin variant DV24Y
phos (fast, tight-
binding, competitive inhibitor). (A) Dose-response curves
of thrombin (1.65 nM) inhibited by DV24Y
phos (0.03 nM, 0.1 nM,
0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM and
1000 nM) in S2238 (100 mM) showed a right shift with increased
pre-incubation time due to cleavage. IC50 are 8.6760.45 nM
without pre-incubation (& solid line) and 12.461.2 nM with
20 min pre-incubation (# dotted line) (n=3, error bars represent
S.D.). (B) Thrombin (1.65 nM) inhibition was tested with
DV24Y
phos (0.39 nM, 0.78 nM, 1.56 nM, 3.13 nM, 6.25 nM,
12.5 nM, 25 nM, 50 nM, 100 nM and 200 nM) in S2238
(100 mM) (& solid line). Apparent inhibition constant Ki9 obtained
by fitting data to equation (2), describing fast and tight-binding
inhibitors, is 10.461.0 nM. Ki calculated from equation (3),
describing competitive inhibitors, the inhibition constant is
0.32760.032 nM (n=3, error bars represent S.D.).
(TIF)
Figure S16 Variegin variant DV24K10RY
phos (fast, tight-
binding, competitive inhibitor). (A) Dose-response curves of
thrombin (1.65 nM) inhibited by DV24K10RY
phos (0.03 nM,
0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM,
300 nM and 1000 nM) in S2238 (100 mM) showed a right shift
with increased pre-incubation time due to cleavage. IC50 are
4.6460.78 nM without pre-incubation (& solid line) and
7.8061.80 nM with 20 min pre-incubation (# dotted line)
(n=3, error bars represent S.D.). (B) Thrombin (1.65 nM)
inhibition was tested with DV24K10RY
phos (0.39 nM, 0.78 nM,
1.56 nM, 3.13 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM, 100 nM
and 200 nM) in S2238 (100 mM) (& solid line). Apparent
inhibition constant Ki9 obtained by fitting data to equation (2),
describing fast and tight-binding inhibitors, is 4.7860.57 nM. Ki
calculated from equation (3), describing competitive inhibitors, is
0.15060.018 nM (n=3, error bars represent S.D.).
(TIF)
Figure S17 Variegin variant DV24Y
sulf (fast, tight-bind-
ing, competitive inhibitor). (A) Dose-response curves of
thrombin (1.65 nM) inhibited by DV24Y
sulf (0.05 nM, 0.15 nM,
0.45 nM, 1.5 nM, 4.5 nM, 15 nM, 45 nM, 150 nM, 450 nM and
1500 nM) in S2238 (100 mM) showed a right shift with increased
pre-incubation time due to cleavage. IC50 are 1.6660.18 nM
without pre-incubation (& solid line) and 2.0260.29 nM with
20 min pre-incubation (# dotted line) (n=3, error bars represent
S.D.). (B) Thrombin (1.65 nM) inhibition was tested with
DV24Y
sulf (0.20 nM, 0.39 nM, 0.78 nM, 1.56 nM, 3.13 nM,
6.25 nM, 12.5 nM, 25 nM, 50 nM and 100 nM) in S2238
(100 mM) (& solid line). Apparent inhibition constant Ki9 obtained
by fitting data to equation (2), describing fast and tight-binding
inhibitor, is 1.7860.47 nM. Ki calculated from equation (3),
describing competitive inhibitors, is 0.05660.015 nM (n=3, error
bars represent S.D.).
(TIF)
Figure S18 Variegin variant DV24K10RY
sulf (fast, tight-
binding, competitive inhibitor). (A) Dose-response curves of
thrombin (1.65 nM) inhibited by DV24K10RY
sulf (0.05 nM,
0.15 nM, 0.45 nM, 1.5 nM, 4.5 nM, 15 nM, 45 nM, 150 nM,
450 nM and 1500 nM) in S2238 (100 mM) showed a right shift
with increased pre-incubation time due to cleavage. IC50 are
1.3960.17 nM without pre-incubation (& solid line) and
1.6660.21 nM with 20 min pre-incubation (# dotted line)
(n=3, error bars represent S.D.). (B) Thrombin (1.65 nM)
inhibition was tested with DV24K10RY
sulf (0.20 nM, 0.39 nM,
0.78 nM, 1.56 nM, 3.13 nM, 6.25 nM, 12.5 nM, 25 nM, 50 nM
and 100 nM) in S2238 (100 mM) (& solid line). Apparent
inhibition constant Ki9 obtained by fitting data to equation (2),
describing fast and tight-binding inhibitors, is 1.3360.19 nM. Ki
calculated from equation (3), describing competitive inhibitors, is
0.042060.0061 nM (n=3, error bars represent S.D.).
(TIF)
Figure S19 Variegin variant MH18Y
sulf (fast, tight-
binding, noncompetitive inhibitor). (A) Dose-response
curves of thrombin (1.65 nM) inhibited by MH18Y
sulf (0.03 nM,
0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM
and 1000 nM) in S2238 (100 mM) are independent of pre-
incubation time. IC50 are 1.2660.18 nM without pre-incubation
(& solid line) and 1.1760.14 nM with 20 min pre-incubation (#
dotted line) (n=3, error bar represents S.D.). (B) Thrombin
(1.65 nM) inhibition was tested with MH18Y
sulf (0.20 nM,
0.39 nM, 0.78 nM, 1.56 nM, 3.13 nM, 6.25 nM, 12.5 nM,
25 nM, 50 nM and 100 nM) in S2238 (100 mM) (& solid line).
Apparent inhibition constant Ki9 obtained by fitting data to
equation (2), describing fast and tight-binding inhibitors, is
1.2560.18 nM. Ki calculated from equations (4) and (5),
describing noncompetitive inhibitors, is 1.2560.18 nM (n=3,
error bar represents S.D.).
(TIF)
Figure S20 Noncompetitive inhibition of thrombin by
MH22. s-Variegin binds to both the non-prime and prime
subsites of thrombin active site and is cleaved between Lys-Met.
After cleavage, the fragment C-terminal to the scissile bond
(MH22) noncompetitively inhibits thrombin. The chromogenic
substrate S2238 binds mainly to the non-prime subsites and is
cleaved between Arg and para-nitroaniline (pNA). The overlaps
between s-variegin and S2238 binding sites resulted in the
observed competitive inhibition. In contrast, the noncompetitive
inhibition observed for MH22 showed the lack of overlaps
between MH22 and S2238 even in the S19 subsite (red box).
Indeed, no density was observed for P19 Met in the present
structure, most likely reflects the lack of contact with thrombin and
hence leaves a free S19 site for the binding of pNA moiety when
MH22 is bound to thrombin.
(TIF)
Table S1 A list of possible direct hydrogen bonds between s-
variegin and thrombin calculated based on the online server PISA
[28].
(TIF)
Materials and Methods S1 A detailed account for the selection
and use of equations to fit the data of thrombin inhibitions is
available in Materials and Methods S1.
(DOC)
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